Government Pricing & Compliance Analyst

Mallinckrodt Pharmaceuticals; Hazelwood (MO); Hybrid; USD 80,000 - 96,000; Full time

Job summary

Keenova is seeking a Government Pricing Analyst to ensure accurate calculation, analysis, audit, and submission of federal pricing for government programs. This role collaborates with Legal, Regulatory, Finance, Commercial, and Compliance to ensure compliant reporting and timely data submission.

The position supports state price transparency and new drug launch pricing, with a focus on AMP, BP, ASP, 340B, and VA/DoD reporting.

Qualifications

• Bachelor's degree in Business, Accounting, Finance, Public Policy, or related field, or equivalent experience.
• At least 3 years of government pricing or related pharmaceutical financial analysis.
• Strong understanding of AMP, BP, ASP, 340B, FSS/VA pricing.
• High proficiency in Excel and Model N experience.
• Ability to work cross-functionally with Legal, Finance, Commercial, Regulatory, and Compliance.

Responsibilities

• Calculate, review, or audit government price reporting programs per approved methodologies (AMP/BP/ASP, 340B, FSS).
• Maintain Model N pricing system accuracy and inputs.
• Ensure timely submission of federal price reports (Medicaid/Medicare/VA/340B).
• Perform analytical reviews and validate pricing compliance with federal regs and internal policies.
• Support new drug launch pricing reporting, including AMP/BP/ASP calculations and FDA listings.

Skills

Strong Excel

Cross-functional collaboration

Analytical ability

Attention to detail

Communication skills

Time management

Education

Bachelor's degree in Business/Accounting/Finance/Public Policy or related field

Tools

Model N

Job description

Keenova is seeking a Government Pricing Analyst to ensure accurate calculation, analysis, audit, and submission of federal pricing for government programs. This role collaborates with Legal, Regulatory, Finance, Commercial, and Compliance to ensure compliant reporting and timely data submission.

The position supports state price transparency and new drug launch pricing, with a focus on AMP, BP, ASP, 340B, and VA/DoD reporting.